Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study

• मुख्य लेखकों: Amy S. Paller (लेखक), Carsten Flohr (लेखक), Lawrence F. Eichenfield (लेखक), Alan D. Irvine (लेखक), Jamie Weisman (लेखक), Jennifer Soung (लेखक), Ana Pinto Correia (लेखक), Chitra R. Natalie (लेखक), Claudia Rodriguez Capriles (लेखक), Evangeline Pierce (लेखक), Sarah Reifeis (लेखक), Renata Gontijo Lima (लेखक), Clara Armengol Tubau (लेखक), Vivian Laquer (लेखक), Stephan Weidinger (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Adis, Springer Healthcare, 2023-06-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Abstract Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disorder with limited treatment options for adolescents with moderate-to-severe disease. Lebrikizumab, a monoclonal antibody targeting interleukin (IL)-13, demonstrated clinical benefit in previous Phase 3 trials: ADvocate1...